BJCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BJCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bioject Medical Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2011 was $0.23 Mil. Bioject Medical Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2011 was $0.00 Mil. Bioject Medical Technologies's Total Stockholders Equity for the quarter that ended in Sep. 2011 was $1.05 Mil. Bioject Medical Technologies's debt to equity for the quarter that ended in Sep. 2011 was 0.21.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bioject Medical Technologies's Debt-to-Equity or its related term are showing as below:
The historical data trend for Bioject Medical Technologies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioject Medical Technologies Annual Data | |||||||||||||||||||||
Trend | Mar01 | Mar02 | Dec03 | Dec04 | Dec05 | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial |
![]() |
![]() |
0.26 | 0.92 | 1.44 | 0.09 | - |
Bioject Medical Technologies Quarterly Data | ||||||||||||||||||||
Dec06 | Mar07 | Jun07 | Sep07 | Dec07 | Mar08 | Jun08 | Sep08 | Dec08 | Mar09 | Jun09 | Sep09 | Dec09 | Mar10 | Jun10 | Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | |
Debt-to-Equity | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | 0.37 | 0.21 |
For the Medical Instruments & Supplies subindustry, Bioject Medical Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Bioject Medical Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bioject Medical Technologies's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Bioject Medical Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2010 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0 | + | 0) | / | 0.381 | |
= | 0.00 |
Bioject Medical Technologies's Debt to Equity Ratio for the quarter that ended in Sep. 2011 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.225 | + | 0) | / | 1.053 | |
= | 0.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioject Medical Technologies (OTCPK:BJCT) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Bioject Medical Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
James C Gale | director | 152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019 |
Sanders Morris Harris Inc/fa | 10 percent owner, other: See General Remarks | 600 TRAVIS, SUITE 5900, HOUSTON TX 77002 |
David S Tierney | director | C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080 |
Edward L Flynn | director, 10 percent owner | 211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921 |
Life Sciences Opportunities Fund Ii Lp | 10 percent owner | 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
Lof Partners Llc | other: See general remarks | 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
Life Sciences Opportunities Fund Instittutional Ii Lp | 10 percent owner | 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019 |
Randal D Chase | director | 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7 |
Brigid Makes | director | 20245 SW 95TH AVENUE, TUALATIN OR 97062 |
J Michael Redmond | officer: Sr. VP Bus Dev. | 10 CANTERBURY ROAD, WINDHAM NH 03087 |
Elan Corp Plc | 10 percent owner | TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000 |
Elan International Services Ltd | 10 percent owner | C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2 |
Elan Pharmaceutical Investments Ltd | 10 percent owner | 102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999 |
John P Gandolfo | officer: CFO | 62 TERRACE ROAD, WAYNE NJ 07470 |
Grace K Fey | director | 1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.